Boehringer discontinues PDE-9A inhibitor for AD

Boehringer Ingelheim GmbH (Ingelheim, Germany) discontinued development of BI 409306 to treat Alzheimer's disease after the candidate missed the efficacy endpoints in two Phase

Read the full 244 word article

User Sign In